Zoetis Services LLC

Sebastian C J Steiniger

Steven Alan Dunham

William Dunkle

Catherine Rugg

Gary Francis Bammert

Steven A Dunham

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of NGF related disorders, particularly in for the management of pain.

Humanized anti-NGF antibodies and methods of treating pain thereof

A monoclonal antibody, or antigen-binding portion thereof is provided that specifically binds to a region on a mammalian IL-31 protein involved with interaction of the IL-31 protein with its co-receptor, wherein the binding of said antibody to said region is impacted by mutations in a 15H05 epitope binding region selected from: a region between about amino acid residues 124 and 135 of a feline IL-31 sequence represented by SEQ ID NO: 157 (Feline_IL31_wildtype); a region between about amino acid residues 124 and 135 of a canine IL-31 sequence represented by SEQ ID NO: 155 (Canine_IL31); and a region between about amino acid residues 118 and 129 of an equine IL-31 sequence represented by SEQ ID NO: 165 (Equine_IL31). Such antibodies can be in the form of veterinary compositions useful for treating IL-31-mediated disorders in cats, dogs, or horses.

Interleukin-31 monoclonal antibodies for veterinary use

Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies

Canine anti-NGF antibodies and methods of treating pain thereof

Felinized anti-NGF antibodies and methods of treating pain

Nucleic acids encoding a canine antibody which binds nerve growth factor and vectors and host cells thereof

The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.

Anti-NGF antibodies and methods thereof

Growing community of inventors

Kalamazoo, MI, United States of America

Sebastian C J Steiniger